Date:5/23/2012

of leading global medical devices industry executives. The report provides data and analysis on buyer expenditure, procurement, and developments within the global medical devices industry. This report includes key topics such as global medical devices industry buyer expenditure and procurement behaviors and strategies. This report identifies the threats and opportunities within the global medical devices industry, economic outlook trends, and business confidence within global medical devices industry executives.Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviors, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research has created this primary-research based report by gathering the opinions of multiple stake holders in the value-chain of the global medical devices industry.What is the current market landscape and what is changing? Overall, the key changes forecast in the business structure for medical devices manufacturers in 2012 have not changed considerably from those identified in 2011. The top three key changes forecast for 2012 include the introduction of 'new products and services', business 'expansion in current market' and 'improving operational efficiency', while, in 2011, emphasis was on 'new products and services' and business 'expansion in current market and abroad'.What are the key drivers behind recent market changes? As a technology-driven market, new, efficient, and cost-effective products and services are always in demand, driving manufacturing companies towards innovative offerings. Evidencing this trend, in February 2012, Boston Scientific, US, a company that develops, manufactures, and markets medical devices, got approval from the US Food and Drug Administration (FDA) for two of its new products, Ion paclitaxel-eluting platinum chromium coronary stent system and Taxus Liberte pac
'/>"/>

SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)